Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Rebecca Porter, MD, PhD is a Medical Oncologist and an active translational and clinical researcher in the Gynecologic Oncology Program in the Dana-Farber Cancer Institute's Susan F. Smith Center for Women's Cancers. Dr. Porter received her MD (2013) and PhD (2011) from the University of Rochester Medical Center. Her PhD research was in the area of hematopoiesis and hematologic malignancies. She then completed Internal Medicine residency at Brigham and Women's Hospital and Hematology/Oncology fellowship training at Dana-Farber Cancer Institute and Massachusetts General Hospital. Her post-doctoral research focused on subtypes of pancreas cancer and the role of the tumor microenvironment on influencing differential responses to therapies. Since specializing in gynecologic cancer, she is now engaged in laboratory, translational and clinical research efforts focused on several areas of ovarian cancer, including developing new biomarkers, testing novel therapy combinations and understanding risk of therapy-related secondary cancers.
Dana-Farber Cancer Institute450 Brookline AvenueBoston, MA 02215Get Directions
Dana-Farber Cancer Institute - Chestnut Hill300 Boylston StreetNewton, MA 02459Get Directions